On February 27, Aimi Vaccines (06660) issued an announcement announcing that its mRNA respiratory syncytial virus vaccine has been approved by the U.S. Food and Drug Administration (FDA) for clinical trials. This is the first time that the company has obtained FDA approval for clinical trials, marking an important progress in its internationalization strategy. The announcement mentioned that in preclinical animal trials, the specific IgG antibody titer, true virus neutralizing antibody titer, and specific T cell immunity of the vaccine were significantly higher than those of the internationally marketed control vaccines, showing the competitiveness of its research and development results.

Respiratory syncytial virus is an important pathogen that causes respiratory infections in infants and the elderly. At present, there is no approved antiviral specific drug for this virus in the world, so vaccination has become an effective means to prevent severe infection. As one of the earliest companies in China to develop mRNA vaccines, the company has established a mature research and development system and a production workshop that meets GMP standards, which can quickly realize the industrialization of vaccines. With the launch of the vaccine, the company is expected to usher in a new growth point in performance.

https://finance.eastmoney.com/a/202502273331295532.html